Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326)

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia 2014-09, Vol.20 (5), p.674-681
• Main Authors: Solano Trujillo, M. H., Stasyshyn, O., Rusen, L., Serban, M., Lamas, J. L., Perina, F. G., Urasinski, T., Oh, M., Knowlton, W. B., Valenta-Singer, B., Pavlova, B. G., Abbuehl, B.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Blood Coagulation - drug effects; Blood Coagulation Factor Inhibitors - blood; Child; Coagulants - adverse effects; Coagulants - pharmacokinetics; Coagulants - therapeutic use; Cross-Over Studies; Drug Substitution - standards; Factor IX - adverse effects; Factor IX - therapeutic use; Female; haemophilia B; Hemophilia B - drug therapy; Hemophilia B - immunology; Hemorrhage - epidemiology; Humans; Incidence; Male; Middle Aged; pdFIX (Immunine®); previously treated patients; Prospective Studies; Recombinant Proteins - adverse effects; Recombinant Proteins - pharmacokinetics; Recombinant Proteins - therapeutic use; rFIX (Rixubis®); safety; Young Adult
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/hae.12444

Summary The ability to switch between coagulation factors safely is of common interest to haemophilia patients and treating physicians. This is the first formal prospective comparative evaluation of safety, efficacy and incremental recovery of a plasma‐derived FIX (pdFIX) and a recombinant FIX (rFIX) in the same haemophilia B patients following a switch from pdFIX Immunine® to a recently developed rFIX Bax326 product. Patients (aged